Moteur de recherche d’entreprises européennes
UK funding (696 056 £) : Lancement du triage intelligent par l’IA pour les cancers gastro-intestinaux inférieurs dans le West Yorkshire Ukri01/05/2024 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Lancement du triage intelligent par l’IA pour les cancers gastro-intestinaux inférieurs dans le West Yorkshire
| Abstract | This proposal launches an innovative blood test as a solution to the growing challenge of urgent cancer referrals and early diagnosis. Developed in partnership with the NHS in West Yorkshire since 2017, the test is designed for multiple pathways, but this project focuses on Lower Gastrointestinal (Lower GI) cancers, such as Bowel. Bowel cancer is the fourth most common cancer in the UK and one of the most deadly. Between 2022-23, 560,000 people were referred with possible symptoms of Lower GI cancers in England, but only 3% were actually diagnosed with cancer. Just half received a confirmed diagnosis within the NHS 28-day target and of those with cancer, only 41.7% started treatment within the target of 62 days. Referrals have been rising 12% a year for over a decade, putting ever increasing strain on a pathway already heavily impacted by workforce pressures, particularly in endoscopy. The PinPoint Test uses AI to analyse a range of markers in blood, having learned patterns from over 370,000 patients and identifying which of those patterns might mean cancer. The result is a simple and clear indicator: the chance that a patient has cancer. As a decision support system for clinicians, the test will help target resources for accelerated access to care. If the result is a high risk of cancer, the patient is prioritised for further testing and consultations. The earlier a patient can be diagnosed, the better their chance of a full recovery. If the test result suggests a very low risk of cancer, the patient may not need to go to hospital at all. Reassured by the result, their GP can monitor symptoms or look for other possible causes. The ability to rapidly rule in _and_ out with a simple blood test will improve the patient journey, help clinicians save lives and contribute to NHS early detection goals. As a software product the PinPoint Test is regularly updated. Each new version gets better at calculating the risk of cancer. This project is designed to make the test available to the public for the first time and build on the work already completed in this, our home region. |
| Category | Launchpad |
| Reference | 10107317 |
| Status | Active |
| Funded period start | 01/05/2024 |
| Funded period end | 30/04/2026 |
| Funded value | £696 056,00 |
| Source | https://gtr.ukri.org/projects?ref=10107317 |
Participating Organisations
| PINPOINT DATA SCIENCE LIMITED |
£673 824,00 |
| UNIVERSITY OF EXETER |
£22 232,00 |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Pinpoint Data Science Ltd., High Wycombe, Royaume Uni.
